KRAS and neoplasm: De novo KRAS mutations reduce the sensitivity of colorectal cells to EGFR‐targeted therapy [29] and CRC tumours also develop resistance to anti‐EGFR therapy by acquiring mutations in RAS [14, 25, 26].